In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.

The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.

This year the Sport Connect Forum, organized by Interros Group and the Russian International Olympic Committee, gathered more than three hundred attendees from the sports industry. The main themes were Global Market Changes and Best Local Projects.

At the sixth annual Russian Pharma Awards 2017, Polyoxidonium, a Russian combination product that is an immunomodulator, detoxifier, and antioxidant, took the prize for «Product of choice for treating and preventing acute viral respiratory infection in children».

Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.